SII Adar Poonawalla

Photo: The Times of India

Fraudsters Dupe SII Of Rs 1 Crore In Name Of CEO Adar Poonawalla

Fraudsters duped Covid-19 vaccine maker Serum Institute of India (SII) of more than Rs 1 crore. As per police source, the fraudster sent a message in the name of SII CEO Adar Poonawalla, asking for a transfer of money. The fraud occurred between the afternoons of September 8-9, following which a complaint was registered with the Pune Police. Senior official Pratap Mankar registered a case and launched an investigation.

Sat, 10 Sep 2022 - 07:24 PM / by Varsha Joshi

Tags: CEO Adar Poonawalla, SII, fraudster, pune police, Duped

Adar Poonawalla

Photo: The Indian Express

SII Adar Poonawalla Speaks About Monkeypox Vaccine In India

As monkeypox cases are rising in India, the Serum Institute of India (SII) which manufactured the Covid-19 vaccine, spoke about the possibility of a monkeypox vaccine in India. SII CEO Adar Poonawalla said, "We are talking to Novovax. We really need to see whether there will be a lot of demand or whether in three to four months it fizzles out." Moreover, he ruled out manufacturing from scratch amid time issues.

Tue, 26 Jul 2022 - 05:44 PM / by Varsha Joshi

Tags: Monkeypox, vaccine, SII, Adar Poonawalla, Cases

Covid-19 vaccine

Photo: News 18

Covishield Vaccine Prices Slashed To Rs 225, Says Adar Poonawalla

Ahead of the nationwide booster dose COVID-19 vaccination drives, the SII CEO Adar Poonawalla slashed the prices of Covishield from Rs 600 to Rs 225.  On April 9, Poonawalla tweeted, "SII has decided to revise the price of COVISHIELD vaccine for private hospitals from Rs.600 to Rs 225 per dose". Notably, the GoI announced a booster dose for the 18+ population at private vaccination centers in India from… read-more

Sat, 09 Apr 2022 - 05:30 PM / by Varsha Joshi

Tags: SII, Adar Poonawalla, Covid-19 Vaccine, COVISHIELD, Booster Dose

Courtesy: The Times of India

SII CEO Adar Poonawalla

Photo: Hindustan Times

SII To Launch Covavax For Children In Mid 2022: Adar Poonawalla

The Serum Institute of India CEO Adar Poonawalla announced to launch COVID-19 vaccine against children (3+). Addressing an event at SII, on December 14, Poonawalla said, Covavax is an Indian made version of the US-based Novavax. It is currently under trial and is showing excellent results on children. If successful, Covavax will be launched by mid-2022 in India, protecting kids against the COVID-19 virus. 

Tue, 14 Dec 2021 - 07:09 PM / by Varsha Joshi

Tags: SII, Adar Poonawalla, Covavax, children, Covid-19

Courtesy: The Siasat Daily

Covishield vaccine.

Photo: Live Law

Serum Institute Resumes Export Of Covishield Vaccine

The Serum Institute of India (SII) On November 26 resumed the export of Covishield, a made-in-India vaccine against Covid-19. The export service has been resumed under the global vaccine sharing programme namely 'COVAX', reported PTI. ''The first batches of the vaccine left the SII manufacturing facility in Pune,'' said the company. So far, the SII produced close to 1.25 billion vaccine doses. 

Fri, 26 Nov 2021 - 09:10 PM / by Varsha Joshi

Tags: SII, COVISHIELD, Exports, Global, COVAX

SII to boost Covishield production upto 200 MIllion doses from October

Photo: BioSpectrum Asia

SII To Boost Covishield Production To 200 Million Doses From Oct

CEO of Serum Institute of India (SII), Adar Poonawalla addressed a virtual conference with Executive Chairperson of Biocon Biologics (BBL) Kiran Mazumdar Shaw to announce their strategic alliance on September 17. Reportedly, SII was looking to scale up its research facilities with BBL. Also, the alliance aims to increase the production of Covishield Vaccines from 160 million doses monthly to 200 million doses from October.

Sat, 18 Sep 2021 - 02:31 PM / by Muskan Arora

Tags: Covid-19, COVISHIELD, SII, Covid Vaccine, Biocon Biologics, Adar Poonawalla

Courtesy: The Indian Express

Covid-19 Vaccines

Photo: Vaccines for India

Central Issues Guidelines To Identify Fake Covid-19 Vaccines

According to a report by WHO on September 5, fake versions of Covishield are in the South-East Asian and African markets. To assure originality in vaccines Central Government has issued guidelines to identify them based on their label, color, etc. The Serum Institute of India administers Covishield, Bharat Biotech Covaxin, and Russian vaccine Sputnik V to 18+ people. However, India has vaccinated 684.6 million doses as of yet.

Mon, 06 Sep 2021 - 12:25 PM / by Ettishree Shukla

Tags: Covid-19, Coronavirus Vaccines, WHO, Central Government, SII

Courtesy: Hindustan Times


Photo: NDTV

DCGI Approves SII's Request To Manufacture Sputnik V In India

The Drug Controller General of India on June 4 approved the Serum Institute of India's request to manufacture Russian COVID-19 vaccine Sputnik-V. Adar Poonawalla-owned organisation has been granted permission to examine, test and analyse the vaccine in India. SII CEO Poonawalla thanked the Ministry of External Affairs and POTUS Joe Biden for relaxing the restrictions on vaccine manufacture. For the production, SII will join hands with… read-more

Sat, 05 Jun 2021 - 09:25 AM / by Nikita Thakur

Tags: SII, Adar Poonawalla, Sputnik-V, Russia, Covid-19, Covid Vaccine

Courtesy: Zee Business

Adar Poonawalla.

Photo: Business Standard

Adar Poonawalla Sells His Stakes In Panacea Biotech For Rs 118 Cr

Adar Poonawalla on May 17 transferred his entire 5.15% stake in Panacea Biotech to his company Serum Institute of India for Rs 118 crore. In an open market transaction, Poonawalla sold 3.15 million shares of Panacea Biotech at Rs 373.85 each. SII was already holding 4.98% stake in Panacea, hence, this deal stretches the total stake to 10.13%. Panacea has reportedly collaborated with Bharat Biotech for Covaxin production.

Tue, 18 May 2021 - 01:19 PM / by Harsh Vardhan

Tags: SII, Adar Poonawalla, Panacea Biotech, Covaxin, Bharat biotech

Courtesy: The Economic Times

Adar Poonawalla.

Photo: The Indian Express

Serum Institute To Invest Rs 2,400 Crore, Generate 6,500 Jobs In UK

Vaccine maker the Serum Institute of India will be investing Rs 2,400 crore in Britain to support clinical trials, research and development along with vaccine manufacturing. The deal is a part of the India-UK enhanced trade partnership, which altogether involves an investment of Rs 10,000 crore. According to sources, SII's investment aims to create 6,500 new jobs and intends to generate new business worth over $1 billion in the UK.

Tue, 04 May 2021 - 01:50 PM / by Harsh Vardhan

Tags: India, UK, trade, SII, Investment

Courtesy: The Times of India